An observational study in Aging, sponsored by AgelessRx. Completed at 1 site in United States. Open to participants aged 40 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-13.
Sponsored by AgelessRx · Observational
This study collected real-world evidence to better understand and define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
AgelessRx is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants who sought rapamycin prescription for longevity support, pain reduction, energy improvement, weight loss, mood improvement, sleep improvement, or oral health improvement were included in the study. To be eligible to receive AgelessRx's standard rapamycin treatment protocol, participants had to be ≥40 years of age, without a history of uncontrolled disease. All patients treated with rapamycin and opted for at least one blood draw test between May 1, 2023, and December 15, 2023, were included in this retrospective study.
Exclusion Criteria:
Participants in this group were receiving Compounded Rapamycin (dosages include 5, 10, or 15mg) once per week
Drug: Rapamycin
Participants in this group were receiving Generia Rapamycin (dosages include 2,3,6, or 8mg) once per week
Drug: Rapamycin
Rapamycin in 2 different dosage forms (compounded and generic)
Also known as: Sirolimus, Rapamune, Rapacan, Siromus, Raparen, Rapasim, Sirova
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin
define the relative bioavailability ratio between compounded rapamycin and generic rapamycin, with a specific focus on relative efficacy in increasing rapamycin levels in the blood (blood rapamycin levels).
Time frame: 8 months
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AgelessRx